指南与共识衰弱、肌少症与跌倒

肌少症定义、诊断与治疗:共识正在形成

Sarcopenia definition, diagnosis and treatment: consensus is growing.
指南 / 共识 · Age Ageing · 2022-01-01

肌少症是与年龄增长及多种长期疾病相关的骨骼肌疾病,与活动能力受损、发病率及死亡率增加相关。其定义已从最初关注肌肉量损失转向关注骨骼肌功能尤其是力量损失,欧洲老年人肌少症工作组(EWGSOP)2019年最新修订版是代表性国际定义之一。新成立的全球肌少症领导倡议(GLIS)将致力于制定定义与诊断的国际共识。

要点

  • 肌少症定义已从肌肉量损失转向以骨骼肌功能尤其是力量损失为核心。
  • 肌少症与活动能力受损、发病率及死亡率增加相关,临床识别重要。
  • GLIS将推动制定肌少症定义与诊断的国际共识。

核心结论

  • 肌少症定义已从肌肉量损失演变为聚焦骨骼肌功能尤其是力量损失,国际共识正在增长。

研究设计与样本

  • 本文为综述,未报告系统检索范围与样本量。

主要发现

  • 肌少症是与年龄增长及多种长期疾病相关的骨骼肌疾病,与活动能力受损、发病率及死亡率增加相关。
  • 国际定义如EWGSOP 2019年最新修订版已转向关注骨骼肌功能尤其是力量损失。

关键数值与推荐

  • EWGSOP定义最近于2019年修订,聚焦骨骼肌功能尤其是力量损失。

临床怎么用

  • 临床应关注骨骼肌功能尤其是力量损失,而非仅关注肌肉量。

局限性

  • 本文为综述,未报告系统检索范围与样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sarcopenia is a skeletal muscle disorder that commonly occurs with advancing age as well as with a number of long-term conditions. Recognition in clinical practice is relatively recent but important because of the association between sarcopenia and a range of adverse effects on health including impaired mobility, increased morbidity and mortality. Originally characterised as loss of muscle mass, the definition has evolved to focus on loss of skeletal muscle function, particularly strength, through a number of international definitions such as that of the European Working Group on Sarcopenia in Older People most recently revised in 2019. Progress in the decades ahead is likely to be seen with regard to use of routine health data, prescription of resistance exercise, translation of biology and epidemiology into first in man studies for new treatments, and focus on sarcopenia in low and middle-income countries. Immediate next steps include the newly formed Global Leadership Initiative on Sarcopenia to develop international consensus on definition and diagnosis.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Sayer AA, Cruz-Jentoft A. Sarcopenia definition, diagnosis and treatment: consensus is growing. Age Ageing. 2022. PMID: 36273495. doi:10.1093/ageing/afac220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。